Medpace Holdings, Inc. reported second quarter 2026 financial results, with revenue of $707.3 million, a 17.2% increase from $603.3 million in the prior-year period. GAAP net income for the quarter was $121.4 million, or $4.25 per diluted share, compared to $90.3 million, or $3.10 per diluted share, in the same period last year. The company forecasts 2026 full-year revenue in the range of $2.805 billion to $2.885 billion and GAAP net income between $494.0 million and $514.0 million. Medpace is a clinical contract research organization providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries.